A Phase 1, Open-label Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Single Oral Doses Using Positron Emission Tomography in Healthy Adult Subjects
Latest Information Update: 31 Jul 2023
Price :
$35 *
At a glance
- Drugs Emraclidine (Primary)
- Indications Alzheimer's disease; Schizophrenia
- Focus Pharmacodynamics
- Sponsors Cerevel Therapeutics
- 25 Jul 2023 Status changed from recruiting to completed.
- 15 Feb 2023 Planned End Date changed from 1 Jul 2023 to 1 Oct 2023.
- 15 Feb 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Jun 2023.